{"id":"d97705c9-698b-4a71-b471-9e096823cc53","arxiv_id":"2601.06300","paper_version":2,"verdict":"CONDITIONAL","confidence":"MODERATE","novelty_score":6.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":2,"one_line_summary":"Initial eligibility-criteria text is weakly predictive of later protocol amendments, and a change-aware masked-language-modeling pretraining step improves prediction by about 1.4% relative AUROC.","lead":"This paper builds a benchmark for predicting whether a clinical trial's eligibility criteria will later be changed, using text from the initial protocol. It also introduces a change-aware pretraining variant that nudges the prediction model's AUROC from about 0.70 to 0.71.","discovery_kind":"new_application","skeptic_critique":{"model":"deepseek-v4-flash","headline":"CAMLM pretraining may include test trials' future EC versions, leaking the label into the encoder and inflating the reported gains.","rationale":"The reader's weakest_assumption identified both the Algorithm 1 label-0 shortcut and the unspecified pretraining split. I focus on the latter because it is the most load-bearing for the paper's main methodological claim. If test trials leak into CAMLM pretraining, the reported consistent improvements are not evidence of amendment-sensitive representations; they are evidence of the model seeing the answer key. This is a correctness risk, not just a data-management nit, and it is not acknowledged in the Limitations section. The reader's verdict of CONDITIONAL already captures this uncertainty, so I recommend no change to the verdict. The proposed concrete test is a strict pretraining split or a simple inspection of the pretraining corpus; either would settle the concern. If the split is clean, the verdict should stand as CONDITIONAL pending artifact release; if the split is dirty, the verdict would need to move toward REJECT because the method's core advantage would be unsupported. I agree with the reader that the label-0 assumption is also a concern, but it affects all baselines uniformly and is explicitly acknowledged, whereas the pretraining leakage, if real, would selectively invalidate the paper's headline contribution.","tokens_in":11589,"tokens_out":4048,"duration_ms":41926,"concrete_test":"Rerun the CAMLM experiments with a strict split: construct all CAMLM pretraining version pairs exclusively from the training trials (e.g., 49,678 in AMEND_LLM) and exclude all 6,067 test trials from pretraining. Then fine-tune and evaluate on the same human-labeled test set. If the AUROC gain over BioBERT no longer reaches DeLong significance (p ≤ 0.05) or shrinks to below ~0.5 point, the reported CAMLM improvement is likely a leakage artifact. A cheaper audit: inspect the released pretraining version-pair file for any test-trial NCT IDs; if present, the current Tables 3, 4, and 10 cannot be interpreted as evidence for CAMLM's effectiveness.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The central claim is that CAMLM consistently improves amendment prediction (Abstract; Sec. 4.3, Tables 3, 4, 10). CAMLM pretraining constructs version pairs (E^(t)_i, E^(T)_i) from recorded EC histories (Eq. 4) and trains an MLM objective that preferentially masks tokens in unstable spans. The paper never states that the 6,067 test trials are excluded from this pretraining corpus. If a test trial's initial and final EC versions both appear as a pretraining pair, the encoder is directly trained to predict tokens whose later change is the exact label signal for that trial. At fine-tuning, the representation of the initial EC can then encode information about the final version, artificially boosting AUROC. The reported gains are small (AUROC +1.4–1.5%, AUPRC +2.1%, accuracy +4.0–4.4% relative), so even modest leakage could fully account for them. The ablation in Table 5 compares CAMLM against MLM and Span MLM, but all use the same corpus; only CAMLM selectively emphasizes changed spans, making it uniquely vulnerable to this form of transductive leakage. The paper's Limitations section acknowledges label noise but is silent on pretraining data splits, so the improvement claim is currently unsecured.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"The paper introduces eligibility criteria amendment prediction as a binary classification task: given the initial eligibility criteria (EC) text and metadata from ClinicalTrials.gov, predict whether the EC will be amended in later protocol versions. The authors release two datasets: AMEND (161,970 trials with raw registry-derived labels) and AMEND_LLM (64,641 trials with LLM-denoised labels). They also propose CAMLM, a change-aware masked-language-modeling pretraining strategy that up-weights masking of tokens in historically unstable spans. Evaluation with BioBERT/BERT/Longformer backbones and logistic-regression/random-forest/fine-tuning classifiers shows moderate AUROC (best 0.714 on AMEND, 0.697 on AMEND_LLM) and consistent CAMLM gains. The paper reports bootstrap confidence intervals and DeLong tests, and includes ablations over pretraining strategies.","tokens_in":11920,"tokens_out":3529,"duration_ms":38769,"significance":"If the labels are trustworthy and the pretraining procedure is free of leakage, the paper makes a useful contribution: it is the first ML-ready benchmark for amendment prediction, releases longitudinal EC version histories at scale, and proposes a revision-aware pretraining objective that transfers across encoders. The evaluation protocol is standard, with non-parametric bootstrap errors and DeLong significance tests, and the ablation study (Table 5) is a positive feature. However, the benchmark's validity rests on two unverified assumptions: that ClinicalTrials.gov label-0 entries are true negatives, and that CAMLM pretraining does not include the test trials' future EC versions. Because the reported gains are small (+1.4–1.5% AUROC, +4% relative accuracy), even modest label noise or leakage could change the conclusions.","major_comments":[{"comment":"Algorithm 1 returns 0 whenever ctgov_label=0, so human annotators never review non-amended trials. The gold-standard test set (shared between AMEND and AMEND_LLM) therefore inherits every raw registry label-0 without verification. The Limitations section acknowledges this assumption but only says false negatives 'are expected to be rare' without supporting evidence. Because all reported AUROC/accuracy numbers depend on these unverified negatives, the benchmark's central validity claim is unsecured. The authors should either manually audit a random sample of label-0 test trials, or provide a sensitivity analysis under plausible false-negative rates.","section":"§3.3, Algorithm 1; §5 Limitations"},{"comment":"The paper never states that the 6,067 test trials are excluded from the CAMLM pretraining corpus. Eq. (4) constructs pairs (E^(t)_i, E^(T)_i) from recorded EC histories; if a test trial's initial and final ECs both appear as a pretraining pair, the MLM objective directly trains the encoder to predict tokens whose later change is the exact label signal. The ablation in Table 5 compares CAMLM to MLM and Span MLM on the same corpus, so all variants could benefit equally from any leakage, but CAMLM is uniquely vulnerable because it selectively masks changed spans. The reported gains are small; a held-out pretraining split must be specified and the experiments re-run on a non-leaking corpus before the CAMLM improvement claim is credible.","section":"§3.4, Eq. (4); Tables 3–5"},{"comment":"The 99.34% agreement between LLM-generated labels and human annotations is partly circular. The LLM prompts are explicitly instructed to 'abide by the rules in Algorithm 1', and the human annotators apply the same Algorithm 1. Thus Table 6 largely measures prompt adherence to a shared rule set, not independent label fidelity. The problem is compounded by the early-return in Algorithm 1: both the LLM (through the ctgov_label shortcut? — at least through the same rules) and the humans are constrained by the registry label. An independent evaluation, ideally with clinicians blinded to ctgov_label and to the LLM outputs, is needed to establish that AMEND_LLM labels are truly denoised.","section":"§4.5, Table 6; §3.3"}],"minor_comments":[{"comment":"The text says 'The exact prompts used for denoising are provided in Appendix 5,' but the appendix is lettered 'Appendix A' and the prompts are Figures 4–6. Please fix the cross-reference.","section":"§4.2"},{"comment":"There is a formatting artifact in Rule 3: 'if any criterion is modified such that:then' has a stray colon. Please clean up the pseudo-code.","section":"Algorithm 1"},{"comment":"The header 'Train trials (1 / 0)' is ambiguous. It seems to indicate positive/negative counts, but this should be stated explicitly in the caption.","section":"Table 2"}],"recommendation":"major_revision","confidential_remarks":"The release promise ('We will publicly release code and data once the paper is accepted') is a policy concern for a benchmark paper; the editor may wish to encourage the authors to commit to a release date or a repository regardless of acceptance. The label-0 verification issue is the most serious technical concern; if a sample audit reveals substantial false negatives, the entire benchmark's conclusions could be undermined. The CAMLM leakage issue is also important and should be addressed with a clear pretraining/test split in the revision."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"Plainly: this is a useful paper. It is the first to frame eligibility-criteria amendment forecasting as a supervised NLP problem, and it will release a large-scale versioned dataset from ClinicalTrials.gov. That alone is a real contribution. The LLM denoising decomposition into added/removed/modified criteria is sensible, and the evaluation against a human-labeled test set with bootstrap and DeLong tests is more careful than most benchmark papers.\n\nThe soft spots, in order of importance. First and most load-bearing: the paper never states whether the CAMLM pretraining corpus includes the test trials. CAMLM builds version pairs (initial, final) for every trial with a recorded history and masks tokens in unstable spans. If any test trial appears in that corpus, the encoder has effectively been told which spans in the initial EC were later changed—that is the label. The reported improvements are small (AUROC +1.4–1.5%, AUPRC +2.1%), so even a handful of leaked trials could explain the entire gain. The authors need to state explicitly that test trials were excluded from pretraining and, ideally, re-run the comparison with a clean split. This is an easy fix but a required one.\n\nSecond, Algorithm 1 inherits the registry's label-0 as ground truth without independent verification. The authors acknowledge this in the Limitations, so it is not hidden, but it means the gold standard is only as good as ClinicalTrials.gov's amendment flags. That is a reasonable starting point, but the paper should discuss the direction of the bias.\n\nThird, the LLM/human agreement of 99.34% is partly circular because both follow the same rule set. It measures instruction-following more than label validity. That is fine for scaling, but it should not be presented as independent confirmation.\n\nThe absolute performance is moderate (AUROC ~0.71), so this is a triage tool, not a replacement for expert review. Still, the task is clearly valuable to trial designers, and the benchmark fills a real gap.\n\nThis is for researchers in clinical NLP and trial operations. It deserves a serious referee; I would send it out but require the pretraining split to be clarified and the experiments redone without the leakage possibility before acceptance. I would also ask for the data and code to be released as part of the review.","headline":"Useful new benchmark and task, but the CAMLM improvement claim is not yet secure because the pretraining split is never defined; worth a serious referee.","tokens_in":12352,"tokens_out":3136,"would_cite":true,"duration_ms":32032,"reading_group":"yes","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"Eligibility-criteria amendment risk is predictable from a trial's initial protocol text, and a revision-aware pretraining method consistently improves that prediction, reaching AUROC 0.714 on a 162,000-trial benchmark.","keywords":["eligibility criteria amendments","clinical trial protocols","amendment prediction","change-aware masked language modeling","LLM label denoising","trial design","natural language processing","protocol version histories"],"falsifier":"Sample several hundred trials that the registry labels as having no eligibility amendment, have two annotators apply the paper's own addition/removal/modification rules to the first and final eligibility versions, and compare with the registry labels; a mismatch rate well above the paper's assumed rarity would invalidate the benchmark's negative labels and the model scores.","tokens_in":11522,"feed_emoji":"🩺","tokens_out":5176,"duration_ms":55880,"temperature":0.7,"pith_summary":"The paper tries to establish that a clinical trial's future eligibility-criteria amendments can be forecast from the initial protocol, before the trial runs. It builds two datasets from public trial version histories — one large and raw, one denoised with an LLM to keep only substantive changes — and it proposes a pretraining strategy that focuses a masked-language model on the parts of eligibility text that historically get revised. Across encoders and classifiers, that strategy gives small but consistent gains, with the best fine-tuned model reaching AUROC 0.714 on the full dataset. The payoff, if true, is that sponsors and regulators could flag fragile protocols early and rework the criteria most likely to be amended, saving time and cost.","feed_headline":"First-draft eligibility text predicts later trial edits","feed_subtitle":"A 162,000-trial benchmark plus revision-aware pretraining flags fragile protocols before submission.","key_machinery":"The load-bearing object is the change-aware masking policy, CAMLM. It takes pairs of an earlier and a final version of a trial's eligibility criteria, computes token-level diffs, and trains a standard masked-language objective with a high masking probability (0.8) inside spans that were deleted or replaced and a low probability (0.05) elsewhere. This biases the encoder toward the kind of content that actually gets amended. The other machinery is the label-construction pipeline: human annotators review only the test split, and an LLM decomposes edits into added, removed, and modified criteria, yielding 99.34% agreement with humans on the test set versus 96.21% for raw registry labels.","core_discovery":"The paper claims that the text of the initial eligibility criteria, plus basic trial metadata, carries predictive signal about whether those criteria will be amended in later versions. It introduces eligibility-criteria amendment prediction as a binary classification task and releases AMEND++: AMEND, a 161,970-trial benchmark built by scraping version histories from the public registry, and AMEND_LLM, a 64,641-trial subset whose training labels are produced by an LLM that classifies edits into added, removed, and modified criteria and ORs the three signals. The central empirical claim is that CAMLM, which masks tokens inside historically unstable spans at high probability and other tokens at","pith_inferences":["Editorial inference: A practical deployment would need to decide whether a 0.70–0.71 AUROC is enough to act on; the utility is likely as a triage screen that selects protocols for human review, not as an automated veto.","Editorial inference: Because the dataset records the full version history, the binary task could be extended to predict how many amendments will occur, when they will happen, or which specific criteria will change — the paper's add/remove/modify decomposition already defines those substeps.","Editorial inference: The change-aware masking recipe is not specific to eligibility criteria; any document type with version histories, such as consent forms or statistical analysis plans, could receive the same treatment.","Editorial inference: The cheapest way to harden the benchmark is an independent audit of trials the registry marks as un-amended; if those negative labels contain hidden errors, all reported scores shift."],"forward_implications":["Initial eligibility text can be scored at design time, so amendment-prone criteria can be targeted before submission.","LLM-denoised labels train better models than raw registry labels, improving AUROC from 0.672 to 0.681 on the same human-labeled test set.","CAMLM's gains are consistent across BERT-style, biomedical, and long-context encoders and across logistic-regression, random-forest, and fine-tuned classifiers.","The released benchmark includes all intermediate eligibility versions, not just first and final, so the history is available for future modeling.","The test set is shared across both datasets and independently annotated, giving a stable evaluation point."],"fun_headline_variants":["AI predicts trial protocol amendments from first draft","Eligibility criteria text reveals future trial edits","New NLP challenge: foresee eligibility amendments","Benchmark AMEND++ predicts trial amendment risk"],"cache_read_input_tokens":2304,"weakest_assumption_plain":"The gold-standard negative labels are never independently reviewed: whenever the registry records no eligibility amendment, the human annotators return label 0, so the entire test-set evaluation silently trusts the registry's completeness; if the registry under-reports amendments, every reported score is built on biased ground truth.","fun_headline_variants_meta":{"raw":{"variants":["AI predicts trial protocol amendments from first draft","Eligibility criteria text reveals future trial edits","New NLP challenge: foresee eligibility amendments","Benchmark AMEND++ predicts trial amendment risk"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000475,"raw_usage":{"total_tokens":2162,"prompt_tokens":677,"completion_tokens":1485,"prompt_tokens_details":{"cached_tokens":256},"prompt_cache_hit_tokens":256,"prompt_cache_miss_tokens":421,"completion_tokens_details":{"reasoning_tokens":1429}},"tokens_in":421,"tokens_out":1485,"duration_ms":11071,"temperature":1.0,"reasoning_tokens":1429,"cache_read_input_tokens":256,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-03T11:26:35.729731+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"Sample several hundred trials that the registry labels as having no eligibility amendment, have two annotators apply the paper's own addition/removal/modification rules to the first and final eligibility versions, and compare with the registry labels; a mismatch rate well above the paper's assumed rarity would invalidate the benchmark's negative labels and the model scores.","supporting_citations":[],"review_version":1}